Buradasınız

Anasayfa » Content

Akut Lösemilerde Minimal Residüel Hastalığın Akım Sitometrisi Yöntemiyle Araştırılması ve Relaps ile Korelasyonu

Determination of Minimal Residual Disease in Acute Leukaemia Using Flow Cytometry and It’s Correlation with Relapse

Journal Name:

  • Uludağ Üniversitesi Tıp Fakültesi Dergisi

Publication Year:

  • 2004

Key Words:

Keywords (Original Language):

Author Name
Abstract (2. Language): 
It’s known that many acute leukemia patients in morphologic remission would eventually relapse due to the persistence of residual leukemic cells. The aim of this study was to evaluate the use of flow cytometry (FC) to detect minimal residual disease (MRD) and the correlation between MRD and relapse-free survival. We have first evaluated the immunophenotypic outcomes of 89 acute leukemia patients during admission and rarely seen coexpressions (UC) were found in 73% of them. Then the initial levels of UC were compared with the levels during complete remission (CR) in 16 alive cases and a significant decrease was observed in 8 cases who have remained in CR for 28-40 weeks of follow-up. However, in 3 cases, coexpression levels in remission were almost the same with the initial levels and 2 of them relapsed after 19 and 30 weeks. These results confirm that FC would be useful in the assessment of MRD and a gradual increase of leukemic cells would be suggestive for subsequent relapse.
Bookmark/Search this post with
Abstract (Original Language): 
Morfolojik olarak tam remisyonda kabul edilen akut lösemi olgularında kemik iliğindeki rezidüel lösemik hücrelerin relapsa yol açtığı bilinmektedir. Bu çalışmanın amacı, minimal residüel hastalık (MRD) tesbitinde akım sitometrisinin kullanımını ve MRD ile hastalıksız yaşam arasındaki korelasyonu değerlendirmektir. Biz önce 89 akut lösemi olgusunda tanıdaki immünfenotip sonuçlarını değerlendirdik ve %73’ünde nadir görülen koekspresyonlar saptadık. Daha sonra, halen hayatta olan 16 olgunun başlangıçta ve komplet remisyondaki (KR) koekspresyon düzeyleri karşılaştırıldı ve 28-40 haftalık takip süresince KR’da kalan 8 olguda anlamlı azalma gözlendi. Buna karşın, olguların 3’ünde, remisyondaki koekspresyon düzeylerinin tanıda belirlenene yakın olduğu dikkati çekti ve bunlardan 2’si 19 ve 30 hafta sonrasında nüksettiler. Bu veriler, rezidüel hastalığın relapsın habercisi olduğunu ve bunu belirlemede akım sitometrisi yönteminin kullanılabileceğini desteklemektedir.
FULL TEXT (PDF): 
PDF icon arastirmax-akut-losemilerde-minimal-residuel-hastaligin-akim-sitometrisi-yontemiyle-arastirilmasi-relaps-ile-korelasyonu.pdf
  • 3
181-187
  • Turkish

REFERENCES

References: 

1. Jennings CD, Foon KA. Flow cytometry: Recent advances in
diagnosis and monitoring of leukemia. Cancer Invest
1997;15: 384-99.
2. Kinney MC, Lukens JN. Classification and differentiation of
the acute leukemias. In: Richard Lee G, Foerster J, Lukens J,
Paraskevas F, Greer JP, Rodgers GM (eds.). Wintrobe’s
Clinical Hematology. 10 th edition. Baltimore: Mass Co
Publishing; 1999. 2209-32.
3. Campana D. Applications of cytometry to study acute
leukemia: in vitro determination of drug sensitivity and
detection of minimal residual disease. Cytometry 1994;18:
68-74.
4. Campana D. Determination of minimal residual disease in
leukaemia patients. Br J Haematol 2003. 121:823-38.
5. San Miguel JF, Martinez A, Macedo A, Vidriales MB,
Lopez-Berges C, Gonzalez M, Caballero D, Garcia-Marcos
MA, Ramos F, Fernandez-Calvo J, Calmuntia MJ, DiazMediavilla J, Orfao A. Immunophenotyping investigation of
minimal residual disease is a useful approach for predicting
in acute myeloid leukemia patients. Blood 1997;90: 2465-70.
6. Macedo A, Orfao A, Gonzalez M, Vidriales MB, LopezBerges MC, Martinez A, San Miguel JF. Immunological
detection of blast cell subpopulations in acute myeloblastic
leukemia at diagnosis: implications for minimal residual
disease studies. Leukemia 1995; 9: 993-8.
7. Wang JC, Beauregard P, Soamboonsrup P, Neame PB.
Monoclonal antibodies in the management of acute leukemia.
Am J Hematol 1995;50: 188-99.
8. Seshadri R. Detection of minimal residual disease in acute
leukemia. Blood 1995; 86: 2452.
9. Morley A. Measurement of minimal residual disease in acute
leukemia. Leukemia 1996;10: 920-2.
10. Jennings CD, Foon KA. Recent advances in flow cytometry:
Application to the diagnosis of hematologic malignancy.
Blood 1997; 90: 2863-92.
11. Sievers EL, Lange BJ, Buckley JD, Smith FO, Wells DA,
Daigneault-Creech CA, Shults KE, Bernstein ID, Loken MR. Akut Lösemide Minimal Residüel Hastalık
187
Prediction of relapse of pediatric acute myeloid leukemia by
use of multidimensional flow cytometry. J Natl Cancer Inst
1996;88: 1483-8.
12. Syrjala M, Anttila VJ, Ruutu T, Jansson SE. Flow cytometric
detection of residual disease in acute leukemia by assaying
blasts co-expressing myeloid and lymphatic antigens.
Leukemia 1994; 8: 1564-70.
13. Lavabre-Bertrand T, George F, Brunet C, Sampol J.
Quantitative immune phenotyping: a new dimension for the
monitoring of hemopoietic malignancies. Nouv Rev Fr
Hematol 1994;36: 373-82.
14. Porwit-MacDonald A, Ivory K, Wilkinson S, Wheatley K,
Wong L, Janossy G. Bcl-2 protein expression in normal
human bone marrow precursors and acute myelogenous
leukemia. Leukemia 1995; 9: 1191-8.
15. Coustan-Smith E, Ribeiro RC, Rubnitz JE, Razzouk BI, Puı
CH, Pounds S, Andreansky M, Behm FG, Raimondi SC,
Shurtleff SA,Downing JR, Campana D. Clinical significance
of residual disease during treatment in childhood acute
myeloid leukaemia. Br J Haematol 2003; 123: 243-52.
16. Reading CL, Estey EH, Huh YO, Claxton DF, Sanchez G,
Terstappen LW, O’Brien MC, Baron S, Deisseroth AB.
Expression of unusual immunophenotype combinations in
acute myelogenous leukemia. Blood 1993; 81: 3083-90.
17. Macedo A, Orfao A, Vidriales MB, Lopez-Berges MC,
Valverde B, Gonzalez M, Caballero MD, Ramos F, Martinez
M, Fernandez-Calvo J. Characterization of aberran
phenotypes in acute myeloblastic leukemia. Ann Hematol
1995; 0: 189-94.
18. Macedo A, San Miguel JF, Vidriales MB, Lopez-Berges MC,
Garcia-Marcos MA, Gonzalez M, Landolfi C, Orfao A.
Phenotypic changes in acute myeloid leukaemia:
implications in the detection of minimal residual disease. J
Clin Pathol 1996; 49: 15-8.
19. Campana D, Coustan-Smith E, Behm FG. The definition of
remission in acute leukemia with immunologic techniques.
Bone Marrow Transplant 1991; 8: 429-37.
20. Macedo A, Orfao A, Ciudad J, Gonzalez M, Vidriales B,
Lopez-Berges MC, Martinez A, Landolfi C, Canizo C, San
Miguel JF. Phenotypic analysis of CD34 subpopulations in
normal human bone marrow and its application for the
detection of minimal residual disease. Leukemia 1995; 9:
1896-901.
21. Bradstok K, Bianchi A, Makrynikola V, Filshie R, Gottlieb
D. Long-term survival and proliferation of precursor-B acute
lymphoblastic leukemia cells on human bone marrow stroma.
Leukemia 1996; 10: 813-20.
22. Orfao A, Ciudad J, Lopez-Berges MC, Lopez A, Vidriales B,
Caballero MD, Valverde B, Gonzalez M, San Miguel JF:
Acute lymphoblastic leukemia (ALL): detection of minimal
residual disease (MRD) at flow cytometry. Leuk Lymphoma
1994; 13: 87-90.
23. Campana D, Pui C-H: Detection of minimal residual disease
in acute leukemia: Methodologic advances and clinical
significance. Blood 1995; 85: 1416-34.

Thank you for copying data from http://www.arastirmax.com